$Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. CORRECTness and CONCURency$

Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. CORRECTness and CONCURency

Colon cancer therapy currently includes at least 3 cytostatic agents and 6 targeted drugs, combinations of which constitute many different treatment regimens. Nevertheless, as shown by various clinical studies, the use of oxaliplatin, irinotecan and fluoropyrimidine regimens in conjunction with mono...

Full description

Bibliographic Details
Main Authors:	R. T. Ayupov, A. A. Izmailov, K. V. Menshikov, A. V. Sultanbaev, A. F. Nasretdinov, R. R. Rakhimov, Sh. I. Musin, N. I. Sultanbaeva
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2021-12-01
Series:	Медицинский совет
Subjects:	metastatic colorectal cancer third line therapy regorafenib targeted therapy antiegfr bevacizumab panitumumab cetuximab aflibercept
Online Access:	https://www.med-sovet.pro/jour/article/view/6579

Similar Items

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01)

The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy
by: Changjing Cai, et al.
Published: (2022-09-01)

Modern possibilities of targeted therapy in metastatic colorectal cancer
by: V A Gorbunova
Published: (2015-12-01)

Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study
by: Yi‐Hsin Liang, et al.
Published: (2023-07-01)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
by: Alessandro Ottaiano, et al.
Published: (2018-05-01)

The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
by: Alexios Matikas, et al.
Published: (2015-03-01)

The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and part review of technology appraisal No. 118): a systematic review and economic model
by: M Hoyle, et al.
Published: (2013-04-01)

Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies
by: Françoso A, et al.
Published: (2017-01-01)

An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
by: Gerardo Rosati, et al.
Published: (2022-11-01)

STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER
by: V. A. Gorbunova
Published: (2015-05-01)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
by: Adithya Chennamadhavuni, et al.
Published: (2022-06-01)

Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
by: Ankur Bahl, et al.
Published: (2020-06-01)

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
by: Hiroya Taniguchi, et al.
Published: (2020-06-01)

Targeted drugs in the second line anticancer therapy of disseminated colorectal cancer
by: K. A. Vorontsova, et al.
Published: (2015-12-01)

Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis
by: Qian Wu, et al.
Published: (2022-08-01)

The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER)
by: Paweł Michał Potocki, et al.
Published: (2023-09-01)

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
by: Meiqin Yuan, et al.
Published: (2022-03-01)

Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene
by: A. F. Nasretdinov, et al.
Published: (2020-12-01)

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
by: G. Sommerhäuser, et al.
Published: (2022-07-01)

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
by: Alessandro Parisi, et al.
Published: (2021-10-01)

A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer
by: Sheng-Chieh Huang, et al.
Published: (2022-03-01)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01)

The role of regorafenib in the treatment of metastatic colorectal cancer
by: A A Tryakin
Published: (2016-06-01)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
by: Yuta Kasagi, et al.
Published: (2013-07-01)

Immunotherapy of advanced hepatocellular carcinoma: case report and literature review
by: K. V. Menshikov, et al.
Published: (2022-06-01)

Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma – A Report of Two Cases
by: G. Ramadori, et al.
Published: (2010-05-01)

Metastasectomy in patients with non-resectable metastatic colorectal cancer receiving chemotherapy and anti-EGFR antibodies: a prospective, non-randomized, multicenter, phase II study
by: M. Yu. Fedyanin, et al.
Published: (2019-06-01)

Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID)
by: Hiroyuki Arai, et al.
Published: (2024-04-01)

Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
by: Yi-Chia Su, et al.
Published: (2022-04-01)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
by: Yu‐Wen Zhou, et al.
Published: (2021-05-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
by: Lu Yang, et al.
Published: (2022-06-01)

Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab
by: Takehito Ehara, et al.
Published: (2020-02-01)

Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer
by: Valeria Internò, et al.
Published: (2020-09-01)

Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients
by: Gerber Peter, et al.
Published: (2012-02-01)

Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices
by: L. V. Bolotina, et al.
Published: (2018-11-01)

Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
by: Alessandro Parisi, et al.
Published: (2020-05-01)

Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
by: Carlo Signorelli, et al.
Published: (2023-06-01)

Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis
by: Carlo Signorelli, et al.
Published: (2023-12-01)

The optimization of second-line therapy for metastatic colorectal cancer: new targeted therapy options
by: E V Artamonova, et al.
Published: (2016-03-01)

The use of regorafenib in colorectal cancer
by: Marina I Sekacheva, et al.
Published: (2019-06-01)